1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 IgA Nephropathy (IgAN) - Introduction
4.1 Overview
4.2 Epidemiology (2019-2024) and Forecast (2024-2034)
4.3 Market Overview (2019-2024) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 IgA Nephropathy (IgAN) - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 IgA Nephropathy (IgAN) - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2024-2034)
8 IgA Nephropathy (IgAN) - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 IgA Nephropathy (IgAN) - Unmet Needs
10 IgA Nephropathy (IgAN) - Key Endpoints of Treatment
11 IgA Nephropathy (IgAN) - Marketed Products
11.1 List of IgA Nephropathy (IgAN) Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 IgA Nephropathy (IgAN) - Pipeline Drugs
12.1 List of IgA Nephropathy (IgAN) Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ravulizumab - Alexion AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Batiraxcept - Aravive
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 BION 1301 - Aduro BioTech
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Telitacicept - Yantai Rongchang Pharmaceutical
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. IgA Nephropathy (IgAN) - Attribute Analysis of Key Marketed and Pipeline Drugs
14 IgA Nephropathy (IgAN) - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 IgA Nephropathy (IgAN) - Market Size
14.2.1.1 Market Size (2019-2024)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2019-2024)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 IgA Nephropathy (IgAN) - Market Size
14.3.1.1 Market Size (2019-2024)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2019-2024)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 IgA Nephropathy (IgAN) - Market Size
14.4.1.1 Market Size (2019-2024)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2019-2024)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 IgA Nephropathy (IgAN) - Market Size
14.5.1.1 Market Size (2019-2024)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2019-2024)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 IgA Nephropathy (IgAN) - Market Size
14.6.1.1 Market Size (2019-2024)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2019-2024)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 IgA Nephropathy (IgAN) - Market Size
14.7.1.1 Market Size (2019-2024)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2019-2024)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 IgA Nephropathy (IgAN) - Market Size
14.8.1.1 Market Size (2019-2024)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2019-2024)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 IgA Nephropathy (IgAN) - Market Size
14.9.1.1 Market Size (2019-2024)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 IgA Nephropathy (IgAN) - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2019-2024)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 IgA Nephropathy (IgAN) - Access and Reimbursement Overview
15 IgA Nephropathy (IgAN) - Recent Events and Inputs From Key Opinion Leaders
16 IgA Nephropathy (IgAN) Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 Appendix